Prosecution Insights
Last updated: September 17, 2026
Application No. 18/573,510

NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE

Non-Final OA §112
Filed
Dec 22, 2023
Priority
Jun 22, 2021 — EU 21181009.8 +1 more
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jw Pharmaceutical Corporation
OA Round
2 (Non-Final)
71%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
711 granted / 997 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
63 currently pending
Career history
1044
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
24.2%
-15.8% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 997 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-6, 8-10 and 12-23 are pending in the application. Claim 1, 8-10, 12 and 15-23 are allowed. Claims 2-6, 13 and 14 are rejected. Information Disclosure Statement The Examiner has considered the Information Disclosure Statement(s) filed on April 10th, 2026. Response to Amendment / Argument Applicant traverses the rejection of claims under 35 USC 112(b) based on amendment. Claim 14 is still considered in definite for the reason below. All other objections and rejections made in the previous Office Action that do not appear below have been overcome by Applicant's amendments to the claims. Therefore, arguments pertaining to these objections and rejections will not be addressed. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 14 refers to “the following table” but where the claim does not contain further text. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Parent claim 1 recites a crystalline compound characterized by one or more reflections. Dependent claim 2 recites a crystalline compound characterized by one or more reflections including each recited reflection of parent claim 1 and one additional reflection. First, the dependent claim recites that the crystalline form is characterized by “one or more” such that the explicit language of the dependent claim would suggest that it could be characterized only by the one additional reflection recited in the dependent claim and none of the reflections recited in the independent claim. Second, if the dependent claim need only be characterized by one or more peaks from a list including the same peaks of the independent claim, the dependent claim would cover each embodiment embraced by the independent claim and not provide a narrowing limitation. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Parent claim 1 recites a crystalline compound characterized by one or more reflections. Dependent claim 3 recites a crystalline compound characterized by one or more reflections including each recited reflection of parent claim 1 and five additional reflections. First, the dependent claim recites that the crystalline form is characterized by “one or more” such that the explicit language of the dependent claim would suggest that it could be characterized only by one or more of the additional reflections recited in the dependent claim and none of the reflections recited in the independent claim. Second, if the dependent claim need only be characterized by one or more peaks from a list including the same peaks of the independent claim, the dependent claim would cover each embodiment embraced by the independent claim and not provide a narrowing limitation. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 4 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 4 recites that the crystalline compound is characterized by “one or more” reflections of parent claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 5 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Parent claim 1 recites a crystalline compound characterized by one or more reflections. Dependent claim 5 recites a crystalline compound characterized by one or more reflections including each recited reflection of parent claim 1 and one additional reflection. First, the dependent claim recites that the crystalline form is characterized by “one or more” such that the explicit language of the dependent claim would suggest that it could be characterized only by the one additional reflection recited in the dependent claim and none of the reflections recited in the independent claim. Second, if the dependent claim need only be characterized by one or more peaks from a list including the same peaks of the independent claim, the dependent claim would cover each embodiment embraced by the independent claim and not provide a narrowing limitation. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 6 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Parent claim 1 recites a crystalline compound characterized by one or more reflections. Dependent claim 6 recites a crystalline compound characterized by one or more reflections including each recited reflection of parent claim 1 and five additional reflections. First, the dependent claim recites that the crystalline form is characterized by “one or more” such that the explicit language of the dependent claim would suggest that it could be characterized only by one or more of the additional reflections recited in the dependent claim and none of the reflections recited in the independent claim. Second, if the dependent claim need only be characterized by one or more peaks from a list including the same peaks of the independent claim, the dependent claim would cover each embodiment embraced by the independent claim and not provide a narrowing limitation. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 13 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Grandparent claim 1 recites a crystalline compound characterized by one or more reflections. Parent claim 9 recites NMR properties and dependent claim 13 recites a crystalline compound characterized by one or more reflections including each recited reflection of grandparent claim 1 and five additional reflections. First, the dependent claim recites that the crystalline form is characterized by “one or more” such that the explicit language of the dependent claim would suggest that it could be characterized only by one or more of the additional reflections recited in the dependent claim and none of the reflections recited in the independent claim. Second, if the dependent claim need only be characterized by one or more peaks from a list including the same peaks of the independent claim, the dependent claim would cover each embodiment embraced by the parent claim 9 and not provide a narrowing limitation. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1, 8-10, 12 and 15-23 are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Dec 22, 2023
Application Filed
Feb 26, 2026
Non-Final Rejection mailed — §112
May 06, 2026
Response Filed
Jul 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12698277
2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof
3y 6m to grant Granted Aug 04, 2026
Patent 12698291
PIKFYVE KINASE INHIBITORS
2y 4m to grant Granted Aug 04, 2026
Patent 12668588
METHOD FOR PREPARING INTERMEDIATE OF URACIL COMPOUND CONTAINING ISOXAZOLINE
3y 5m to grant Granted Jun 30, 2026
Patent 12653806
METHODS FOR TREATING COVID-19
3y 2m to grant Granted Jun 16, 2026
Patent 12649714
PROCESS AND INTERMEDIATES FOR PREPARATION OF OMAVELOXOLONE AND SALTS THEREOF
2y 8m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
71%
Grant Probability
84%
With Interview (+12.2%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 997 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month